奥拉西坦联合瑞舒伐他汀对脑梗死患者血清超敏C反应蛋白、白细胞介素-1β、白细胞介素-6的影响

摘要

目的 探讨奥拉西坦联合瑞舒伐他汀治疗脑梗死的临床疗效以及对患者血清超敏C反应蛋白(hs-CRP)、白细胞介素-1β(IL-1β)、白细胞介素-6(IL-6)的影响.方法 选取100例脑梗死患者,随机分为观察组和对照组各50例.对照组采用常规治疗,观察组采用奥拉西坦联合瑞舒伐他汀,观察2组患者的临床疗效,比较治疗前后hs-CRP、IL-1β、IL-6水平.结果 观察组治疗总有效率显著高于对照组(P＜0.05).治疗后,2组hs-CRP、IL-1β、IL-6水平均显著改善(P＜0 05),且观察组显著优于对照组(P＜0.05).结论 采用奥拉西坦联合瑞舒伐他汀治疗脑梗死患者疗效确切,能够显著改善血清hs-CRP、IL-1β、IL-6水平.%Objective To investigate the effects of oxiracetam combined with rosuvastatin on levels of serum hs-CRP,IL-1 β and IL-6 in patients with cerebral infarction.Methods A total of 100 patients with cerebral infarction were selected and randomly divided into observation group and control group.The control group was given conventional cerebral infarction treatment,and the observation group was given oxiracetam combined with rosuvastatin.The clinical efficacy and levels of hsCRP,IL-1β and IL-6 before and 14 days after treatment were compared.Results After treatment,the total effective rate of the observation group was significantly higher than the control group (P ＜0.05).After treatment,the levels of hs-CRP,IL-1β,IL-6 improved significantly in both groups (P ＜ 0.05),and which in the observation group was significantly better than control group (P ＜0.05).Conclusion Oxiracetam combined with rosuvastatin is effective in treatment of patients with cerebral infarction,and it can significantly improve the levels of hs-CRP,IL-1 β and IL-6.